Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that metformin may be more effective than Dianette in treating moderate to severe hirsutism in women with PCOS, while also reducing markers of insulin resistance.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.

This review explores various therapeutic options for managing female hirsutism, emphasizing the effectiveness of low-dose finasteride and cyproterone acetate, but it presents no new clinical results.

Antiandrogen therapy may help treat hidradenitis suppurativa.

This case report describes a patient with a hepatitis C diagnosis whose acral rash, initially unresponsive to psoriasis treatment, showed significant improvement with oral zinc sulfate, suggesting a diagnosis of necrolytic acral erythema.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This study found that Diane®, a combination of cyproterone acetate and ethinyl estradiol, is an effective contraceptive and treatment for acne and seborrhea, but less effective for pronounced hair growth.

In this study, Diane was reported to effectively treat acne, seborrhoea, androgenic alopecia, and mild hirsutism in hirsute women, with its effectiveness influenced by the severity and duration of the condition.

This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.

This study found that a low-dose oral contraceptive containing dienogest provides effective contraception, improves cycle stability, and may reduce excessive scalp and skin oiliness, with high user satisfaction.

This study reported that Diane-35 treatment over 6-9 months reduced hair loss, hair thinning, and seborrhoea in women with androgenetic alopecia.

This study suggests that Aldactone may be more effective than Diane in reducing hair growth, despite having minimal impact on hormone levels.

Women's acne improvement with antibiotics is not linked to signs of high male hormones.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This meta-analysis reported that dienogest and combined oral contraceptives had comparable efficacy and tolerability for endometriosis treatment, with therapeutic choice suggested to be based on patient preference and clinical history.

This abstract details known indications, categories, and potential reactions for various drugs, including anorexiants, estrogens, NSAID analgesics, cardiac glycosides, and migraine preventives, without reporting new clinical results.

This study found that both Diane 35 plus spironolactone and Diane 35 plus finasteride were equally effective and safe for treating hirsutism and acne in Indian women over a 12-month period.

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

The estradiol valerate/dienogest oral contraceptive helps with heavy periods, may improve acne and symptoms in PCOS, and doesn't affect sexual function.

This review discusses severe insulin resistance syndromes, highlighting their diagnostic challenges, potential novel therapies like leptin replacement, and suggests metformin and lifestyle changes in its absence; no new clinical results are reported.

This review discusses hormonal influences and treatment considerations in female acne, particularly highlighting the role of androgens in persistent or resistant cases, and reports no new clinical findings.

This article reviews the prescription-only cream eflornithine for managing facial hirsutism in women and reports no new clinical results; the authors evaluate its potential role in treatment.

In this study, daily administration of 100mg DHEA for 16 weeks in women with adequate ovarian reserve did not modify metabolic or reproductive variables, apart from increased antral follicular count and anti-Müllerian hormone levels.

This study found that taking a daily oral dose of 50mg DHEA for one year had no significant impact on blood lipids, insulin sensitivity, or the endometrium in postmenopausal women with low libido.

This study observed a strong overall reduction in the use of CPA/EE in the Netherlands, despite similar proportions of users with acne or other hyperandrogenic conditions before and after the referral procedure.

This meta-analysis found that while both Dienogest and GnRH analogues effectively managed endometriosis-related pain, Dienogest reduced recurrence rates and hot flushes but increased irregular bleeding, making it a safer option due to fewer side effects.

This review discusses perceptions and side effects of depot medroxyprogesterone acetate and emphasizes the importance of educating teens to enhance compliance; it reports no new clinical findings.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

This study found that the combination of ethinylestradiol and desogestrel significantly decreased hair growth and hormone levels in hirsute women, suggesting a relationship between hormone changes and treatment effectiveness.